The Deadline Is Coming: Cannabis Operators Brace for a Pivotal Spring in Federal Policy

The Deadline Is Coming: Cannabis Operators Brace for a Pivotal Spring in Federal Policy

The calendar on the wall of every cannabis lobbyist's office is circled in red on two dates this spring: May 24 and June 29. They mark, respectively, the deadline to formally request participation in the most consequential federal cannabis rulemaking in history, and the day the hearing actually begins. What happens in between — and in the weeks that follow — may determine the legal status of cannabis in America for the next generation.

In April, the DOJ issued a final order placing FDA-approved marijuana products and state-licensed medical cannabis into Schedule III of the Controlled Substances Act, fulfilling a key component of President Trump's December 2025 executive order on cannabis research. But that action was widely understood as a first step, not a destination. The broader rulemaking — which could move all cannabis, including recreational products, out of Schedule I — is what the June 29 DEA administrative hearing is designed to adjudicate.

The mechanics matter. By May 24, anyone seeking to participate in the hearing — industry groups, patient advocates, researchers, law enforcement associations — must file written notice of intent with the DEA. The hearing is scheduled to run through July 15. The process is adversarial in structure: participants can present evidence and cross-examine witnesses, meaning that well-funded opposition groups and well-funded industry advocates will face each other in a formal legal setting. The outcome will feed into a final rule that could expand or contract the April order's scope. What the administration does with the administrative law judge's recommendations, and how quickly, is another matter entirely.

The White House's public messaging has been characteristically mixed. Drug czar Sara Carter Bailey clarified last week that even under Schedule III, adult-use cannabis "is still illegal" under federal law, a statement clearly intended to tamp down expectations among consumers who assumed the April order changed the picture at the dispensary level. For recreational users, it didn't — and won't, regardless of what the June hearing produces. Schedule III would, if applied broadly, primarily benefit medical operators and researchers, not the adult-use market that generates the vast majority of the industry's revenue.

At the state level, the week produced a mix of progress and friction. In Idaho — one of a small handful of states with no cannabis access whatsoever — advocates with the National Medicine Alliance of Idaho submitted more than double the required signatures to qualify a medical cannabis measure for November's ballot, a development that could bring medical cannabis to a state that has resisted it for decades. Signature challenges are expected, but the sheer volume submitted gives advocates a buffer that prior Idaho campaigns lacked. In Iowa, advocates were urging the governor to sign legislation that would double the number of permitted medical dispensaries, a more modest expansion reflecting the cautious political terrain of the Midwest.

Meanwhile, the 2026 Farm Bill, which passed the House in a 224-200 vote, is creating a separate and equally fraught policy drama around hemp. The bill redefines hemp using a total-THC standard — counting THCA alongside delta-9 THC — a change that would effectively narrow the testing window that allowed the explosion of hemp-derived THC products to enter mainstream retail over the past several years. Critically, the House version does nothing to delay or revise the November 2026 enforcement timeline on intoxicating hemp products set by last year's appropriations law, leaving an entire product category — hemp-derived THC beverages, gummies, and vapes — in a state of legal precarity heading into the holiday retail season.

What this means for operators is layered. For state-licensed medical cannabis companies, the Schedule III order is already producing real, tangible benefits: the ability to deduct ordinary business expenses starting in tax year 2026, the prospect of IRS guidance on retroactive 280E relief, and an expedited federal pathway for research partnerships. For recreational operators, the landscape is more ambiguous — improved tax treatment flows their way only if and when broader rescheduling is finalized, which could take years. For hemp companies banking on the continued expansion of intoxicating hemp-derived products, the Farm Bill's trajectory and the November enforcement deadline are existential questions.

The layered nature of all this is not an accident. Cannabis policy in America has always moved in pieces, with different constituencies winning different concessions at different times, rarely in concert. What's unusual about the spring of 2026 is the sheer number of consequential decisions converging simultaneously. The industry has grown accustomed to waiting — but the wait, at least this season, may actually be coming to an end.